CIPLA's weekly performance was modest, with a 1.45% return, lagging behind its peers SUNPHARMA and DIVISLAB. The stock's volatility was moderate at 14.66%, which is relatively lower compared to GRASIM but higher than SUNPHARMA. The Sharpe Ratio of 0.52 indicates that the stock's return was not adequately compensated for the risk taken. Overall, CIPLA underperformed its peers this week and exhibited moderate risk.

[Volatility: 14.66%]